BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19602546)

  • 1. Prediction of muscle-invasive bladder cancer using urinary proteomics.
    Schiffer E; Vlahou A; Petrolekas A; Stravodimos K; Tauber R; Geschwend JE; Neuhaus J; Stolzenburg JU; Conaway MR; Mischak H; Theodorescu D
    Clin Cancer Res; 2009 Aug; 15(15):4935-43. PubMed ID: 19602546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
    Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
    Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis.
    Theodorescu D; Wittke S; Ross MM; Walden M; Conaway M; Just I; Mischak H; Frierson HF
    Lancet Oncol; 2006 Mar; 7(3):230-40. PubMed ID: 16510332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMP3 expression in urothelial carcinomas of the urinary bladder.
    Ozdemir NO; Türk NS; Düzcan E
    Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder.
    Sitnikova L; Mendese G; Liu Q; Woda BA; Lu D; Dresser K; Mohanty S; Rock KL; Jiang Z
    Clin Cancer Res; 2008 Mar; 14(6):1701-6. PubMed ID: 18347170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness.
    Karasavvidou F; Barbanis S; Pappa D; Moutzouris G; Tzortzis V; Melekos MD; Koukoulis G
    Arch Pathol Lab Med; 2008 Dec; 132(12):1912-5. PubMed ID: 19061289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study.
    Frantzi M; van Kessel KE; Zwarthoff EC; Marquez M; Rava M; Malats N; Merseburger AS; Katafigiotis I; Stravodimos K; Mullen W; Zoidakis J; Makridakis M; Pejchinovski M; Critselis E; Lichtinghagen R; Brand K; Dakna M; Roubelakis MG; Theodorescu D; Vlahou A; Mischak H; Anagnou NP
    Clin Cancer Res; 2016 Aug; 22(16):4077-86. PubMed ID: 27026199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum microRNA expression signatures as novel noninvasive biomarkers for prediction and prognosis of muscle-invasive bladder cancer.
    Jiang X; Du L; Duan W; Wang R; Yan K; Wang L; Li J; Zheng G; Zhang X; Yang Y; Wang C
    Oncotarget; 2016 Jun; 7(24):36733-36742. PubMed ID: 27167342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.
    Gupta M; Milbar N; Tema G; Pederzoli F; Chappidi M; Kates M; VandenBussche CJ; Bivalacqua TJ
    World J Urol; 2019 Oct; 37(10):2051-2058. PubMed ID: 30671639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Capillary electrophoresis coupled to mass spectrometry for proteome analysis. An innovative diagnostic method for prostate and bladder cancer].
    Wittke S; Schiffer E; Bauer HW
    Urologe A; 2007 Jul; 46(7):733-9. PubMed ID: 17318473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance of Preoperative Urine Cytology in Low-grade Non-muscle-invasive Bladder Cancer.
    Kiyoshima K; Akitake M; Shiota M; Takeuchi A; Takahashi R; Inokuchi J; Tatsugami K; Yokomizo A; Eto M
    Anticancer Res; 2016 Feb; 36(2):799-802. PubMed ID: 26851042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder Urothelial Carcinoma Diagnosis by Liquid-based Cytology.
    Lee H; Kim K; Woo J; Park J; Kim H; Lee KE; Kim H; Kim Y; Moon KC; Kim JY; Park IA; Shim BB; Moon JH; Han D; Ryu HS
    Mol Cell Proteomics; 2018 Sep; 17(9):1788-1802. PubMed ID: 29950347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder.
    Mangrud OM; Gudlaugsson E; Skaland I; Tasdemir I; Dalen I; van Diermen B; Baak JP; Janssen EA
    Hum Pathol; 2014 Jul; 45(7):1496-503. PubMed ID: 24796506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
    Klatte T; Seligson DB; Rao JY; Yu H; de Martino M; Kawaoka K; Wong SG; Belldegrun AS; Pantuck AJ
    Cancer; 2009 Apr; 115(7):1448-58. PubMed ID: 19195047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UBC
    Ecke TH; Weiß S; Stephan C; Hallmann S; Arndt C; Barski D; Otto T; Gerullis H
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.
    Poyet C; Buser L; Roudnicky F; Detmar M; Hermanns T; Mannhard D; Höhn A; Rüschoff J; Zhong Q; Sulser T; Moch H; Wild PJ
    J Clin Pathol; 2015 Oct; 68(10):819-24. PubMed ID: 26251520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternatives to cytology in the management of non-muscle invasive bladder cancer.
    Amiel GE; Shu T; Lerner SP
    Curr Treat Options Oncol; 2004 Oct; 5(5):377-89. PubMed ID: 15341676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the nuclear matrix protein 22 Bladder Chek test™ in the diagnosis of residual urothelial cancer before a second transurethral resection of bladder cancer.
    Balci M; Tuncel A; Guzel O; Aslan Y; Sezgin T; Bilgin O; Senel C; Atan A
    Int Urol Nephrol; 2015 Mar; 47(3):473-7. PubMed ID: 25649031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.